Compare YMT & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YMT | CATX |
|---|---|---|
| Founded | 2011 | 1983 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.6M | 211.1M |
| IPO Year | 2025 | N/A |
| Metric | YMT | CATX |
|---|---|---|
| Price | $1.04 | $4.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $11.78 |
| AVG Volume (30 Days) | 356.8K | ★ 7.2M |
| Earning Date | 06-09-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $20,502,945.00 | $1,075,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.85 | $1.60 |
| 52 Week High | $6.05 | $6.16 |
| Indicator | YMT | CATX |
|---|---|---|
| Relative Strength Index (RSI) | 34.60 | 68.66 |
| Support Level | $0.85 | $4.44 |
| Resistance Level | $1.84 | $5.00 |
| Average True Range (ATR) | 0.20 | 0.81 |
| MACD | -0.11 | 0.08 |
| Stochastic Oscillator | 21.11 | 68.42 |
Yimutian Inc is the largest agricultural B2B platform in mainland China. It provide a comprehensive set of digital solutions to facilitate agricultural product transactions, ranging from searching, matching, to transaction facilitation and settlement. The company pride itself as the go-to platform for merchants by leveraging its inventive technology and industry know-how. Its platform had over 38 million merchants. It has also established approximately 12 offline stores in mainland China to trade agricultural products at cultivation and production sites with sellers and buyers.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.